CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research

SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology.

Research Grants up to $50,000 will be awarded to projects focused on accelerating the pace of preclinical innovation and novel PDX methodologies that improve clinical predictions with sound science. The program offers an opportunity for investigators to receive funding for projects that may not receive support through traditional funding channels. Submitted proposals will be reviewed and selected by CrownBio’s Scientific Steering Committee with the goal of realizing breakthroughs in preclinical oncology strategies.

“Crown Biosciences recognizes the importance of supporting investigators in early discovery,” said Laurie Heilmann, Chief Business Officer at Crown Bioscience. “By investing in the brightest scientific minds, we can evolve the current research paradigms and establish novel tools that will help researchers and drug developers address global health challenges.”

For more details on the innovative grant program or to submit a proposal visit: Innovative Grant Program of Oncology Preclinical Early Discovery

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Media Enquiries:

Jody Barbeau
Crown Bioscience Inc. marketing@crownbio.com

CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research

SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology.

Research Grants up to $50,000 will be awarded to projects focused on accelerating the pace of preclinical innovation and novel PDX methodologies that improve clinical predictions with sound science. The program offers an opportunity for investigators to receive funding for projects that may not receive support through traditional funding channels. Submitted proposals will be reviewed and selected by CrownBio’s Scientific Steering Committee with the goal of realizing breakthroughs in preclinical oncology strategies.

“Crown Biosciences recognizes the importance of supporting investigators in early discovery,” said Laurie Heilmann, Chief Business Officer at Crown Bioscience. “By investing in the brightest scientific minds, we can evolve the current research paradigms and establish novel tools that will help researchers and drug developers address global health challenges.”

For more details on the innovative grant program or to submit a proposal visit: Innovative Grant Program of Oncology Preclinical Early Discovery

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Media Enquiries:

Jody Barbeau
Crown Bioscience Inc. marketing@crownbio.com

Ads

You May Also Like

Precision Therapeutics to Hold Business Update Conference Call on April 2, 2018

MINNEAPOLIS, March 26, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the ...

CrownBio推出新型人源化免疫療法標靶模型

聖地牙哥, May 04, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience是Crown Bioscience International (TWSE:6554) 的全資附屬公司,亦是一家全球藥物發現和開發服務公司,為促進腫瘤、炎症、心血管和代謝疾病研究提供轉化平台,透過推出一種新型轉基因CD3E模型以促進免疫腫瘤(I/O  /  ...